Methods for treating and/or collecting information regarding neurological disorders, including language disorders

Information

  • Patent Grant
  • 7565199
  • Patent Number
    7,565,199
  • Date Filed
    Tuesday, December 9, 2003
    20 years ago
  • Date Issued
    Tuesday, July 21, 2009
    14 years ago
Abstract
Methods for treating and/or collecting information regarding neurological disorders, including language disorders. A method in accordance with one embodiment directing a patient to perform a language-based task, directing information to be collected, with the information corresponding to a level of neural activity in the patient's brain while the patient performs the language-based task, and, based at least in part on the information, selecting a stimulation site within the patient's skull for receiving an electrode coupleable to an electrical current. In further embodiments, at least one electrode can be placed at the stimulation site, and the patient's language disorder can be reduced by applying electrical stimulation directly to the stimulation site via the at least one electrode.
Description
TECHNICAL FIELD

The present invention is directed toward methods for treating and/or collecting information regarding neurological disorders, including language disorders, for example, aphasias.


BACKGROUND

A wide variety of mental and physical processes are controlled or influenced by neural activity in particular regions of the brain. For example, various physical or cognitive functions are directed or affected by neural activity within the various regions of the cerebral cortex. For most individuals, particular areas of the brain appear to have distinct functions. In the majority of people, for example, the areas of the occipital lobes relate to vision; the regions of the left inferior frontal lobes relate to language; portions of the cerebral cortex appear to be involved with conscious awareness, memory, and intellect; and particular regions of the cerebral cortex as well as the basal ganglia, the thalamus, and the motor cortex cooperatively interact to facilitate motor function control.


Aphasias are neurological disorders that affect the language centers of the brain. Aphasias are typically caused by brain lesions that result from a stroke or head injury. Different aphasias result from damage to different portions of the brain's language centers. For example, Broca's aphasia typically results from a large frontal lobe lesion and causes the patient to speak with great effort in a nonfluent manner, while generally not affecting the patient's comprehension of single words and simple sentences. Wernicke's aphasia typically results from damage to the left temporal lobe of the brain and impacts the patient's comprehension of words and sentences, usually without affecting the patient's fluency. Global aphasia can affect both Broca's area and Wernicke's area of the brain and can accordingly adversely affect both the patient's comprehension and speech fluency. Conduction aphasia is caused by damage to structures that interact with the major language areas of the brain. Conduction aphasia does not have as substantial an effect on the patient's comprehension or fluency as do other aphasias, but reduces the patient's ability to repeat sentences verbatim or easily name pictures and objects.


Practitioners have developed imaging techniques to isolate the portions of the brain affected by various aphasias. For example, Perani, et al. disclose identifying and tracking neurological functioning connected with language-based activities by obtaining functional magnetic resonance imaging (fMRI) data while the patient executes language-based tasks (see “A fMRI Study of Word Retrieval in Aphasia,” Brain and Language 85 (2003) pp. 357-368). Practitioners have also treated aphasia, for example, with conventional and/or melodic speech therapies, with drugs (e.g., amphetamines and other neuro-stimulatory agents) and with transcutaneous magnetic stimulation (TMS) applied to the brain. However, these techniques all suffer from drawbacks. In particular, the efficacies of speech therapy and drug-based techniques have not been conclusively demonstrated, and the effects of TMS are short-lived.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1A is a flow chart illustrating a method for treating a language disorder in accordance with an embodiment of the invention.



FIG. 1B is a flow chart illustrating details of a method for selecting a stimulation site used for treating language disorders in accordance with another embodiment of the invention.



FIG. 2 is a partially schematic, isometric illustration of a human brain illustrating areas associated with language comprehension and production and suitable for stimulation in accordance with embodiments of the invention.



FIG. 3 is a partially schematic generally horizontal section through a human brain illustrating reference features suitable for locating stimulation sites in accordance with other embodiments of the invention.



FIG. 4 is a partially schematic, isometric illustration of a human brain having an electrode assembly positioned for stimulation in accordance with an embodiment of the invention.



FIG. 5 is a partially schematic, isometric illustration of a human brain and an electrode assembly configured in accordance with another embodiment of the invention.



FIG. 6 is a partially schematic, side view of a patient's upper body, head and neck, along with an electrode assembly positioned in accordance with yet another embodiment of the invention.



FIG. 7 is a cross-sectional illustration of an electrode system positioned in a patient's skull in accordance with an embodiment of the invention.



FIG. 8 is a partially schematic cross-sectional side view of an electrode system positioned in a patient's skull and having an electrode urged against a portion of the patient's brain in accordance with another embodiment of the invention.



FIG. 9 is a partially schematic, side elevational view of an electrode system positioned in the patient's skull in accordance with still another embodiment of the invention.



FIG. 10 is a flow chart illustrating a method for collecting information while stimulating a patient's brain in accordance with another embodiment of the invention.





DETAILED DESCRIPTION

The following disclosure describes several methods for collecting information regarding neurological disorders, including language disorders, and methods for treating such disorders using electrical stimulation, for example, cortical stimulation. Cortical stimulation has been applied in other contexts, for example to enhance the recovery of cortical functions after a brain injury affecting motor capabilities. Several features of methods in accordance with embodiments of the invention are set forth and described in FIGS. 1A-10. It will be appreciated that methods in accordance with other embodiments of the invention can include additional procedures or features different than those shown in FIGS. 1A-10. Additionally, methods in accordance with several embodiments of the invention may not include all of the features shown in these Figures.



FIG. 1A is a flow chart illustrating a method 100 for treating language disorders in accordance with an embodiment of the invention. In one aspect of this embodiment, the method 100 includes selecting a brain stimulation site located within the patient's skull (method portion 102). At least one electrode can then be positioned at the stimulation site (method portion 104). The method 100 can further include coupling the electrode(s) to a source of electrical potential (method portion 106) and at least reducing a language disorder of the patient by applying electrical stimulation directly to the stimulation site via the electrode(s) (method portion 108).


In one particular aspect of this embodiment, the patient's language disorder can be entirely eliminated. In another particular aspect of this embodiment, the effects of the disorder can at least be diminished. In a further aspect of either embodiment, the stimulation site can be selected to be on the left side of the patient's brain, e.g., at or proximate to the language centers of the brain. In another aspect of these embodiments, the homologous structures on the right side of the patient's brain can be stimulated in addition to or in lieu of stimulating the left side of the patient's brain. Further details of the areas of the brain selected for stimulation, and the devices that apply the stimulation are discussed later with reference to FIGS. 2-10.


Referring next to FIG. 1B, the process of selecting a stimulation site (process portion 102) can include directing the patient to perform a language-based task (process portion 110). The method can further include directing information to be collected while the patient performs the language-based task, with the information corresponding to a level of neural activity in the patient's brain while the task is performed (process portion 112). In one embodiment, the foregoing process portions can be completed while the patient is under the influence of an amphetamine or other neuroexcitatory drug, and in other embodiments, such agents are not present in the patient's body during the procedure.


In one embodiment, process portion 112 can be carried out at least in part by a human operator, for example, a technician or physician who operates an imaging system. In another embodiment, the process of directing the collection of information can be performed partially or entirely by a computer, for example, by a hardware- and/or software-based routine that collects the information corresponding to the level of neural activity. In either embodiment, the information can take several forms and/or can correspond to the level of neural activity in the patient's brain by virtue of any of several techniques, as described below. As is also described below, a practitioner can direct the patient to perform one or more of a variety of language-based tasks that generate a neural response corresponding to the collected information.


In a particular aspect of an embodiment of the invention, the language-based task performed by the patient does not require the patient to actually vocalize. Instead, the patient can be directed to merely think of a word, letter, phrase or other language component. For example, the patient can be directed to silently generate a verb associated with a common noun, silently repeat a noun, silently retrieve a word based on a letter cue, or silently retrieve a word based on a visual cue. In particular cases, the patient can be directed to think of words beginning with the letter “C,” for example, or can be shown a picture of a cat and asked to think of the word represented by the picture. The patient can also be asked to respond nonverbally to an oral task that requires the patient to understand the difference between two auditory commands. In any of these embodiments, the patient need not use motor neurons to execute the selected task. An advantage of this arrangement is that reducing the number of motor neurons active while the patient performs the selected task can more clearly highlight those areas of the brain associated purely with the cognitive aspect of the language-based task. Put another way, this technique can reduce or eliminate the recorded activity of motor neurons, which might otherwise clutter or obscure the cognitive, language-based information of interest.


In other embodiments, the patient can be directed to perform any of the above tasks verbally. The practitioner can direct the patient to perform a verbal task when, for example, the motor activity associated with speech production will clearly not obscure neural responses associated with non-motor aspects of language-based tasks, and/or when it is desirable to locate and/or stimulate regions of the brain associated with motor aspects of the language-based tasks. In still further embodiments, the patient can be directed to perform a variety of language-based tasks and the information collected while the patient performs each task can be combined to aid the practitioner in determining a stimulation site. This technique can be used to identify multiple stimulation sites and/or to more definitively or precisely locate a particular stimulation site. In any of these embodiments, the methods described above include collecting information, such as imaging information, while the patient performs the task, as described in greater detail below.


The collected information can take the form of an image, generated using functional magnetic resonance imaging (fMRI) techniques, magnetic resonance imaging (MRI) techniques, computed tomography (CT) techniques, single photon emission computed tomography (SPECT) techniques, positron emission tomography (PET) techniques and/or other techniques. In any of these embodiments, a practitioner can view the image and, based at least in part on the image, identify a stimulation site for treating the language disorder. For example, the images can be color-coded or can have other distinguishing characteristics that allow the practitioner to distinguish active regions from inactive regions. In a particular embodiment, the active regions can be identified by a relatively elevated blood oxygen level, and in other embodiments, these regions can be identified on the basis of other characteristics.


In other embodiments, the foregoing techniques can be used to generate a digital representation of brain activity without necessarily generating a visible image. In a particular aspect of these embodiments, an algorithm or other computer-based method can be used to determine the stimulation site, based upon the digital representation described above. Whether or not the collected information is in the form of a visually accessible image, it can aid the practitioner in determining where to implant electrodes for applying electrical stimulation. The locations for the electrodes and the techniques for placing the electrodes at the stimulation sites are described in greater detail below with reference to FIGS. 2-9.


Methods in accordance with still further embodiments of the invention can include subsets of the method portions shown in FIGS. 1A-1B. For example, a method in accordance with one embodiment of the invention includes directing the patient to perform a language-based task and then directing information to be collected, with the information corresponding to a level of neural activity in the patient's brain while the patient performs the language-based task. The method can further include selecting a stimulation site based at least in part on the information. The stimulation site can be located within the patient's skull and can receive an electrode coupleable to an electrical current.



FIG. 2 is an isometric, left side view of the brain 120 of a patient P. As described above, certain sectors of the brain 120 are typically responsible for language-based tasks. These sectors can be identified using the techniques described above, and can be selected as stimulation sites. Accordingly, the sectors can be targeted to receive direct electrical stimulation for reducing and/or eliminating the effects of a language disorder.


In one embodiment, the targeted areas of the brain 120 can include Broca's area 124 and/or Wernicke's area 125. In other embodiments, sections of the brain 120 anterior to, posterior to, or between these areas can be targeted in addition to or in lieu of targeting Broca's area 124 and Wernicke's area 125. For example, the targeted areas can include the middle frontal gyrus 121, the inferior frontal gyrus 122 and/or the inferior frontal lobe 123 anterior to Broca's area 124. In other embodiments, the areas targeted for stimulation can include the superior temporal lobe 127, the superior temporal gyrus 128, and/or the association fibers of the arcuate fasciculcus 126. In still further embodiments, the targeted areas can include the inferior parietal lobe 129 and/or other structures, including the supramarginal gyrus, angular gyrus, retrosplenial cortex and/or the retrosplenial cuneus of the brain 120.



FIG. 3 is a partially schematic, approximately horizontal section through the brain 120 described above with reference to FIG. 2. The stimulation sites described above with reference to FIG. 2 can be identified with reference to anatomical features of the patient, for example, the patient's nose. In other embodiments, the stimulation site can be identified with reference to fiducials 133 positioned in the patient's skull 132. Accordingly, the location of the fiducials 133 can appear on the image (or other display format) used to present the neural activity information and identify the corresponding stimulation sites.



FIG. 4 is an isometric illustration of the left side 120a of the brain 120 with an electrode assembly 140 positioned to provide stimulation in accordance with an embodiment to the invention. In one aspect of this embodiment, the electrode assembly 140 includes a support 141 carrying a plurality of electrodes 142 (eight are shown in FIG. 4). In a further aspect of this embodiment, the electrode assembly 140 is positioned to cover a plurality of the areas (described above) responsible for carrying out language-based tasks. For example, in one embodiment, the electrode assembly 140 can be sized to extend generally from the inferior frontal lobe 123 to the inferior parietal lobe 129, and can include electrodes 142 located to stimulate any of a plurality of areas between and adjacent to these structures. In any of these embodiments, the electrode assembly 140 can also include a lead 143 coupled to a power supply and/or a pulse system, as described in greater detail below with reference to FIG. 6.


One feature of an embodiment of the electrode assembly 140 described above with reference to FIG. 4 is that it can include an array of electrodes 142 that are spaced apart from each other, for example, along two transverse axes. Accordingly, each electrode 142 can be positioned to stimulate a particular region of the brain 120. An advantage of this arrangement is that a practitioner can stimulate multiple sites of the brain 120 (either simultaneously or sequentially) with a single electrode assembly 140. In one embodiment, the practitioner can stimulate multiple sites of the brain 120 (rather than a single site) to produce enhanced benefits for the patient. In another embodiment, the practitioner can use an electrode assembly 140 having an array of electrodes 142 when it is initially uncertain which area(s) of the patient's brain 120 should be stimulated to produce the most beneficial effect. Accordingly, a practitioner can stimulate a particular area of the brain 120 with one of the electrodes 142, observe the effect on the patient, and if the effect is not the desired effect, stimulate another area of the brain 120 with another of the electrodes 142 and observe the resulting effect, all with a single, implanted assembly 140. In still another embodiment, the practitioner can apply stimulation to different sites for different lengths of time, and/or the practitioner can independently vary other stimulation parameters applied to the electrodes 142. In any of these embodiments, the signal applied to the electrodes 142 can be varied randomly or pseudo-randomly. Further details of the signals applied to the electrodes 142 are described below with reference to FIG. 6.


In another embodiment shown in FIG. 5, the practitioner can implant a generally strip-shaped electrode assembly 540 in the patient P. In one aspect of this embodiment, the electrode assembly 540 can include an elongated support 541 carrying a plurality of linearly aligned electrodes 542 coupled to a lead 543. The electrode assembly 540 can be positioned to extend over a relatively narrow band between the inferior frontal lobe 123 and the inferior parietal lobe 129. In one aspect of this embodiment, the electrode assembly 540 can include six electrodes 542, and in other embodiments, the electrode assembly 540 can include more or fewer electrodes 542. In any of these embodiments, the electrodes 542 can be selectively activated, simultaneously or sequentially, in a manner generally similar to that describe above to provide the patient with a therapeutically effective treatment.


In other embodiments, the electrode assembly can have arrangements other than those described above. For example, other electrode assemblies can have support members with shapes other than those shown in FIGS. 4 and 5, including irregular shapes. In still further embodiments, the electrodes can be distributed over the support members or irregular patterns, for example, to align with sites at the brain 120 most likely to be selected for stimulation.


In one aspect of embodiments described above with reference to FIGS. 4 and 5, the electrode assemblies are positioned over the left hemisphere 120a of the patient's brain because the language centers of the brain are typically concentrated there. In other embodiments, the electrode assemblies can be positioned on the right side 120b of the patient's brain 120 to stimulate right hemisphere neurons. For example, as shown in FIG. 6, an electrode assembly 540 generally similar to that described above with reference to FIG. 5 can be positioned over the right side 120b of the patient's brain 120 between the inferior frontal lobe 123 and the inferior parietal lobe 129. Accordingly, the electrode assembly 540 can be positioned adjacent to the brain structures homologous to those described above with reference to FIGS. 2-4.


In one aspect of this embodiment, the stimulation applied to the right side 120b of the patient's brain 120 can recruit right-side neurons to take over functions normally provided by (now defective) tissue on the left side 120a of the patient's brain 120. In another embodiment, (used, for example, when it is determined that recruiting homologous right-side neurons is actually detrimental to the patient's recovery of language-based functionality), the stimulation is applied to the right side 120b of the patient's brain 120 to impede or inhibit the body's attempts to recruit right-side neurons. In a particular aspect of this embodiment, the manner in which this stimulation is applied (e.g., the level of the voltage or current applied and/or the manner in which the voltage or current is varied or modulated) can determine whether the effect of the right-side neurons is enhanced or inhibited. In another embodiment, the location of the electrodes can determine whether the effect of the right-side neurons is enhanced or inhibited. In either embodiment, it can be advantageous to have a plurality of electrodes 542 (as shown in FIG. 6) available on the right side 120b of the brain 120 to allow flexibility in treating the patient's language-based disorder. The plurality of electrodes 542 can be arranged along a single axis (as shown in FIG. 6), or along multiple axes (e.g., as shown in FIG. 4), or in an irregular pattern. In still another embodiment, the foregoing technique can be used to inhibit the body's attempts to recruit left-side neurons, for example, when it is determined that recruiting such neurons is actually detrimental to the patient's recovery.


In another aspect of an embodiment shown in FIG. 6, the electrode assembly 540 can form a portion of a system 650 that also includes a pulse generator 651. For purposes of illustration, two alternative examples of pulse generators 651 are shown in FIG. 6 as a first pulse generator 651a and a second pulse generator 651b. The first pulse generator 651a can be implanted at a subclavicular location in the patient P, and the second pulse generator 651b can be implanted above the neck, posteriorly to the ear of the patient P. Either pulse generator 651 can be coupled to the electrode assembly 540 with the lead 543 and can provide electrical signals that stimulate the adjacent neurons, as described in greater detail below.


In one embodiment, the electrical signals can be applied to a single one of the electrodes 542 to provide a monopolar pulse of current to a small area of the brain 120. Accordingly, the system 650 can include a return electrode, which can be a portion of a pulse generator 651, or a separate electrode implanted elsewhere in the patient P (e.g., on the other side of the patient's brain 120 or at a subclavicular location). In other embodiments, electrical current can be passed through all of the electrodes 542 or only a subset of the electrodes 542 to activate larger or different populations of neurons. In one aspect of these embodiments, the potential applied to the electrodes 542 can be the same across all of the activated electrodes 542 to provide monopolar stimulation at the stimulation site. In other embodiments, some of the electrodes 542 can be biased with a positive polarity and other electrodes 542 can be biased with a negative polarity. This embodiment provides a bipolar stimulation to the brain 120. The particular configuration of the electrodes 542 activated during treatment can be optimized after implantation to provide the most efficacious therapy for the patient P.


The particular waveform of the applied stimulus depends upon the symptoms of the patient P. In one embodiment, the stimulus includes a series of biphasic, charge balanced pulses. In one aspect of this embodiment, each phase of the pulse is generally square. In another embodiment, the first phase can include a generally square wave portion representing an increase in current above a reference level, and a decrease below the reference level. The second phase can include a gradual rise back to the reference level. The first phase can have a pulse width ranging from about 25 microseconds to about 400 microseconds. In particular embodiments, the first phase can have a pulse width of 100 microseconds or 250 microseconds. The total pulse width can range up to 500 milliseconds.


The voltage of the stimulus can have a value of from about 0.25 V to about 10.0 V. In further particular embodiments, the voltage can have a value of from about 0.25 V to about 5.0 V, about 0.5 V to about 3.5 V, about 2.0 V to about 3.5 V or about 3 V. The voltage can be selected to be below a level that causes movement, speech or sensation in the patient (e.g., subthreshold) or above such a level (e.g., suprathreshold). In certain embodiments, the practitioner may control the current applied to the patient, in addition to or in lieu of controlling the voltage applied to the patient.


The frequency of the stimulus can have a value of from about 25 Hz to about 250 Hz. In particular embodiments, the frequency can have a value of from about 50 Hz to about 150 Hz, or about 100 Hz. The stimulation can be applied for a period of 0.5 hour-4.0 hours, and in many applications the stimulation can be applied for a period of approximately 0.5 hour-2.0 hours, either during language-based therapy (e.g., language comprehension training) or before, during and/or after such therapy. In other embodiments, the stimulation can be applied continuously, or only during waking periods but not during sleeping periods. It may be particularly effective to treat language disorders by applying stimulation before, during, and/or after language-based therapy because the language centers of the brain may be active during many periods of time in addition to active therapy periods. In particular aspects of this embodiment, the characteristics (e.g., current, voltage, waveform, pulse duration, frequency) are different depending on whether the stimulation is applied before, during or after the language-based therapy. In still further embodiments, the stimulation can be applied while a selected drug (e.g., an amphetamine or other neuroexcitatory agent) is active. In other embodiments, such drugs are not administered. Examples of specific electrical stimulation protocols for use with an electrode array at an epidural stimulation site are as follows:


EXAMPLE 1





    • An electrical stimulus having a current of from about 3 mA to about 10 mA, an impedance of 500 to 2000 Ohms, a pulse duration of 160 microseconds, and a frequency of approximately 100 Hz. The therapy is not applied continuously, but rather during 30-120 minute intervals, associated with language-based therapy.





EXAMPLE 2





    • The stimulus has a current of from about 3 mA to about 6 mA, a pulse duration of approximately 150-180 microseconds, and a frequency of approximately 25 Hz-31 Hz. The stimulus is applied continuously during waking periods, but it is discontinued during sleeping periods to conserve battery life of the implanted pulse generator.





EXAMPLE 3





    • The stimulus has a current of from about 3 mA to about 6 mA, a pulse duration of approximately 90 microseconds, and a frequency of approximately 30 Hz. This stimulus is applied continuously during waking and sleeping periods, but it can be selectively discontinued during sleeping periods.





In one aspect of embodiments of the systems described above with reference to FIGS. 4-6, an electrode assembly having multiple electrodes is positioned at the cortex of the brain 120. Further details of such placements are described below with reference to FIGS. 7-9. In other embodiments, portions of the electrode assemblies can extend into or beneath the cortex to stimulate interior portions of the brain 120, including deep brain tissue. In still further embodiments, the electrode assembly can include a single electrode or one or more electrode pairs, also described in greater detail below with reference to FIGS. 7-9.



FIG. 7 is a cross-sectional view of a stimulation system 750 configured and implanted in accordance with an embodiment of the invention. In one aspect of this embodiment, the stimulation system includes a support member 741, an integrated pulse system 751 (shown schematically) carried by the support member 741, and first and second electrodes or contacts 742 (identified individually by reference numbers 742a and 742b). The first and second electrodes 742 are electrically coupled to the pulse system 751 and are carried by the support member 741.


The support member 741 can be configured to be implanted in the skull 132 or another region of a patient P above the neckline. In one embodiment, for example, the support member 741 includes a housing 744 and an attachment element 745 connected to the housing 741. The housing 744 can be a molded casing formed from a biocompatible material, and can have an interior cavity for carrying the pulse system 751 and a power supply. The housing 744 can alternatively be a biocompatible metal or another suitable material. The housing 744 can have a diameter of approximately 1-4 cm, and in many applications the housing 744 can be 1.5-2.5 cm in diameter. The thickness T of the housing 744 can be approximately 0.5-4 cm, and can more generally be about 1-2 cm. The housing 744 can also have other shapes (e.g., rectilinear, oval, elliptical) and other surface dimensions. The stimulation system 750 can weigh 35 g or less and/or can occupy a volume of 20 cc or less. The attachment element 745 can include a flexible cover, a rigid plate, a contoured cap, or another suitable element for holding the support member 741 relative to the skull 132 or other body part of the patient P. In one embodiment, the attachment element 745 includes a mesh, e.g., a biocompatible polymeric mesh, metal mesh, or other suitable woven material. The attachment element 745 can alternatively be a flexible sheet of Mylar, polyester, or another suitable material.


In one aspect of an embodiment shown in FIG. 7, the stimulation system 750 is implanted in the patient P by forming an opening in the scalp 734 and cutting a hole 735 completely through the skull 132. The hole 735 can also pass through the dura mater 736 for subdural applications (shown), or the hole 735 can pass through the skull 132 but not the dura mater 736 for epidural applications. The hole 735 can be sized to receive the housing 744 of the support member 741, and in most applications the hole 735 can be smaller than the attachment element 745. A practitioner can insert the support member 741 into the hole 735 and then secure the attachment element 745 to the skull 132. The attachment element 745 can be secured to the skull 132 using a plurality of fasteners 746 (e.g., screws, spikes, etc.) or an adhesive. In another embodiment, a plurality of downwardly depending spikes can be formed integrally with the attachment element 745 to provide anchors that can be driven into the skull 132.


The embodiment of the stimulation system 750 shown in FIG. 7 is configured to be implanted in the patient P so that the electrodes 742 are juxtaposed to a desired cortical stimulation site. The housing 744 can project from the attachment element 745 by a distance D1 such that the electrodes 742 are positioned at least proximate to the dura mater 736 or the pia mater 737 surrounding the cortex 738. The electrodes 742 can project from the housing 744 as shown in FIG. 7. In the particular embodiment shown in FIG. 7, the electrodes 742 project from the housing 744 by a distance D2 so that the electrodes 742 press against a desired surface of the brain 120. The distance D2 is from 0.1 mm to about 5 cm in some embodiments, and has other values in other embodiments. In still further embodiments, the electrodes 742 are flush with the housing 744. The electrodes 742 can be separate conductive members attached to the housing 744, or the electrodes 742 can be integral surface regions of the housing 744.


The configuration of the stimulation system 750 is not limited to the embodiment shown in FIG. 7. For example, in other embodiments, the housing 744, and the attachment element 745 can be configured to position the electrodes 742 in several different regions of the brain. In particular embodiments, the housing 744 and the attachment element 745 can be configured to position the electrodes 742 deep within the cortex 738 or against the dura mater 736.


The pulse system 751 shown in FIG. 7 generates and/or transmits electrical pulses to the electrodes 742 to stimulate a cortical region of the brain 120. The particular embodiment of the pulse system 751 shown in FIG. 7 is an “integrated” unit in that the pulse system 751 is carried by the support member 741. The pulse system 751, for example, can be positioned within the housing 744 so that the electrodes 742 can be carried by the housing 744 and connected directly to the pulse system 751 without having external leads outside the stimulation system 750. The distance between the electrodes 742 and the pulse system 751 can be less than 4 cm, for example, 0.10 to 2.0 cm. The stimulation system 750 can accordingly provide electrical pulses to the stimulation site without requiring a remote implanted pulse generator, which is connected to the electrodes 742 with surgically tunneled cables. In other embodiments, the pulse generator can be implanted separately from the electrodes, for example, in a manner generally similar to that described above with reference to FIG. 6. In still further embodiments, signals can be transmitted to the electrodes 742 from a remote location outside the patient's body via a wireless (e.g., RF) link.



FIG. 8 is a cross-sectional view of a stimulation system 850 configured and implanted in accordance with an embodiment of the invention. In one aspect of this embodiment, the stimulation system 850 includes a driving element 860 coupled to the electrodes 742 to mechanically urge the electrodes 742 away from the housing 744. In another embodiment, the driving element 860 can be positioned between the housing 744 and the attachment element 745, and the electrodes 742 can be attached directly to the housing 744. The driving element 860 can include a compressible member, for example, an open or closed cell biocompatible compressible foam, or a compressible solid (e.g., silicon rubber). In other embodiments, the driving element 860 can include a fluid-filled bladder, a spring, or any other suitable element that resiliently and/or elastically exerts a force against the electrodes 742.


In one aspect of an embodiment shown in FIG. 8, the driving element 860 is compressed slightly upon implantation so that the electrodes 742 contact the stimulation site. For example, the compressed driving element 860 can gently press the electrodes 742 against the surface of the pia mater 737. It is expected that the driving element 860 will provide a uniform, consistent contact between the electrodes 742 and the pial surface of the cortex 738. The stimulation system 850 is expected to be particularly useful when the implantable device is attached to the skull 132 and the stimulation site is on the pia mater 737 or the dura mater 736. It can be difficult to position the electrodes 742 against the pia mater 737 because the distance between the skull 132 and the dura mater 736 or the pia mater 737 varies as the brain 120 expands and contracts relative to the skull 132, and also because this distance varies from one patient P to another. The driving element 860 of the stimulation system 850 can compensate for the different distances between the skull 132 and the pia mater 737 so that a single type of device can better fit several different patients P. Moreover, the driving element 860 can change the position of the electrodes 742 as the brain 120 moves within the skull 132.



FIG. 9 is a cross-sectional view of a stimulation system 950 configured and implanted in accordance with another embodiment of the invention. The stimulation system 950 can include a support member 941, an integrated pulse system 951 (shown schematically) carried by the support member 941, a driving element 960 carried by the support member 941, and an electrode or contact 942a carried by the driving element 960. The contact 942a is electrically coupled to the pulse system 951 by a lead 943a. The driving element 960 can be a compliant material having a cavity 961 filled with a fluid such as saline or air. In another embodiment, the stimulation system 950 can further include an optional return electrode 942b carried on the opposite side of the support structure 941. The return electrode 942b can be electrically coupled to the pulse system 951 by a return lead 943b.


To implant the stimulation apparatus 960, a burr hole 935 is cut completely through the skull 132 of the patient P at a predetermined location identified according to the methods set forth above. The burr hole 935 can also pass through the dura mater (not shown FIG. 9). After forming the burr hole 935, a ferrule 947 is placed in the burr hole 935, and a threaded barrel 948 is welded or otherwise attached to the ferrule 947. A position ring 949 is then threaded along the threads of the barrel 948 to a desired height. The stimulation system 950 is placed in the burr hole 935 until a rim 952 projecting from the support member 941 engages the position ring 949. A lock ring 953 is then threaded onto the barrel 949 until it engages the rim 952. The position ring 949 and the lock ring 953 hold the support member 941 at a desired height relative to the surface of the patient's brain 120.


In one aspect of the embodiments described above with reference to FIGS. 1A-9, information is collected on the activity of the brain prior to implanting any of the foregoing stimulation systems. Accordingly, the collected information can guide the practitioner as the practitioner determines where to apply the stimulation. In a method in accordance with another embodiment of the invention (shown in FIG. 10), such information can be collected while the stimulation system is activated. For example, a method 1000 in accordance with an embodiment of the invention includes directing a patient to perform a task (process portion 1002), directing information to be collected corresponding to a level of neural activity in the patient's brain while the patient performs the task (process portion 1004), and applying an electrical stimulation to the patient's brain while directing the information to be collected (process portion 1006). In one aspect of this embodiment, the task performed by the patient can be a language-based task, for example, any of the tasks described above with reference to FIGS. 1A-1B. In another embodiment, the task can be another type of task (for example, a motor task) which also generates a detectable response in the patient's brain. In any of these embodiments, the information can take the form of visually accessible images (e.g., using fMRI, MRI, CT, or PET techniques), or the information can take other forms that are not necessarily visually accessible.


The information collected while the stimulation system is active can be used to determine whether the stimulation system is creating the desired response in the patient's brain, and/or whether the response is occurring in the desired area of the patient's brain. This technique can be used to provide feedback on the efficacy of the stimulation system and can also be used to adjust aspects of the stimulation system. For example, when the stimulation system includes a plurality of electrodes, the foregoing technique can be used to determine which of the electrodes is providing the desired response. This technique can also be used to determine whether the voltage level (and/or the variation of the voltage level) of the signals applied to the electrodes produces the desired effect. Accordingly, such techniques can be used in addition to or in lieu of receiving direct feedback from the patient to determine the efficacy of the treatment. Such techniques can also be used to tailor the manner in which the treatment is administered.


From the foregoing, it will be appreciated that specific embodiments of the invention have been described herein for purposes of illustration, but that various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

Claims
  • 1. A method for selecting a stimulation site in a language-disorder patient, comprising: administering a neuroexcitatory drug to a patient;directing a patient to perform a language-based task, including directing the patient to repeat a noun;directing information to be collected while the patient performs the language-based task with the neuroexcitatory drug active in the patient's body, the information corresponding to a level of neural activity in the patient's brain while the patient performs the language-based task; andbased at least in part on the information, selecting a stimulation site within the patient's skull, proximate the dura mater, and outside a cortical surface of the patient's brain for receiving an electrode coupleable to an electrical current.
  • 2. A method for selecting a stimulation site in a language-disorder patient, comprising: administering a neuroexcitatory drug to a patient;directing the patient to perform a language-based task;directing information to be collected, the information corresponding to a level of neural activity in the patient's brain while the patient performs the language-based task with the neuroexcitatory drug active in the patient's body; andbased at least in part on the information, selecting a stimulation site within the patient's skull for receiving an electrode coupleable to an electrical current.
  • 3. The method of claim 2 wherein selecting a stimulation site includes selecting a stimulation site at least proximate to at least one of Broca's area, Wernicke's area, and neuronal connections extending between Broca's area and Wernicke's area.
  • 4. The method of claim 2 wherein selecting a stimulation site includes selecting a stimulation site at least proximate to at least one of the middle temporal gyrus, the retrosplenial cortex and the retrosplenial cuneus of the brain.
  • 5. The method of claim 2 wherein directing the patient to perform a language-based task includes directing the patient to perform a task that requires no verbal output.
  • 6. The method of claim 2 wherein directing the patient to perform a language-based task includes directing the patient to silently generate a verb associated with a common noun.
  • 7. The method of claim 2 wherein directing the patient to perform a language-based task includes directing the patient to retrieve a word based on a letter cue.
  • 8. The method of claim 2 wherein directing the patient to perform a language-based task includes directing the patient to retrieve a word based on a visual cue.
  • 9. The method of claim 2 wherein directing the patient to perform a language-based task includes directing the patient to respond nonverbally to an oral task that requires the patient to understand the difference between two auditory commands.
  • 10. The method of claim 2, further comprising implanting an electrode at least proximate to the stimulation site.
  • 11. The method of claim 2 wherein directing information to be collected includes directing a computer-based routine to collect the information.
  • 12. The method of claim 2, further comprising directing the formation of an image of at least a portion of the patient's brain, with at least a portion of the image having features representative of the information.
  • 13. The method of claim 2 wherein directing information to be collected includes directing the formation an image of at least a portion of the patient's brain, the image including a first region with a characteristic of the first region having a first value, the image further including a second region with a characteristic of the second region having a second value different than the first value.
  • 14. The method of claim 2 wherein directing a patient to perform a language-based task includes directing the patient to perform a first language-based task and wherein directing information to be collected includes directing first information to be collected while the patient performs the first language-based task, and wherein the method further comprises: directing the patient to perform a second language-based task;directing second information to be collected while the patient performs the second language-based task; anddetermining a location for the stimulation site based on both the first information and the second information.
  • 15. The method of claim 2 wherein directing a patient to perform a language-based task includes directing the patient to perform a first language-based task subject to a language disorder and wherein directing information to be collected includes directing first information to be collected while the patient performs the first language-based task, and wherein the method further comprises: monitoring a first image of the patient's brain function while the patient performs the first language-based task;identifying a second language-based task subject to a language disorder;monitoring a second image of the patient's brain function while the patient performs the second language-based task; andcomparing the first and second images to identify at least one stimulation site of the brain.
  • 16. The method of claim 2, further comprising: positioning at least one electrode at the stimulation site;coupling the at least one electrode to a source of electrical potential; andat least reducing a language disorder of the patient by applying electrical stimulation directly to the stimulation site via the at least one electrode while not actively engaging the patient in a language-based task.
  • 17. The method of claim 16 wherein positioning at least one electrode includes implanting the at least one electrode.
  • 18. The method of claim 16 wherein applying an electrical stimulation includes applying an electrical stimulation to the left hemisphere of the brain.
  • 19. The method of claim 16 wherein applying an electrical stimulation includes applying an electrical stimulation to the right hemisphere of the brain.
  • 20. The method of claim 16 wherein at least reducing a language disorder of the patient includes at least reducing an aphasia of the patient.
  • 21. The method of claim 16 wherein applying an electrical stimulation includes applying an electrical stimulation at least proximate to at least one of Broca's area, Wernicke's area, and neuronal connections extending between Broca's area and Wernicke's area.
  • 22. The method of claim 16 wherein applying an electrical stimulation includes applying an electrical stimulation to at least one of the middle temporal gyrus, the retrosplenial cortex and the retrosplenial cuneus of the brain.
  • 23. The method of claim 16, further comprising: administering a neuroexcitatory agent to the patient; andapplying the electrical stimulation while the neuroexcitatory agent is active in the patient's body.
  • 24. The method of claim 16 wherein applying electrical stimulation includes applying electrical stimulation below a level that causes movement, speech or sensation in the patient.
  • 25. The method of claim 16 wherein applying electrical stimulation includes applying electrical stimulation at or above a level that causes movement, speech or sensation in the patient.
  • 26. The method of claim 16 wherein at least reducing a language disorder includes eliminating the language disorder.
  • 27. The method of claim 16, further comprising locating the stimulation site relative to an anatomical feature of the patient.
  • 28. The method of claim 16, further comprising locating the stimulation site relative to a fiducial having a fixed location relative to the patient's skull.
  • 29. The method of claim 16 wherein applying an electrical stimulation includes applying a varying electrical stimulation signal having a frequency of from about 5 Hz to about 200 Hz.
  • 30. The method of claim 16 wherein applying an electrical stimulation includes applying a varying electrical stimulation signal having an electrical potential of from about 0.25 volts to about 5.0 volts.
  • 31. The method of claim 2 wherein directing information to be collected includes directing information to be collected corresponding to blood oxygen levels in the brain.
  • 32. The method of claim 2, further comprising placing an electrode at least proximate to the stimulation site.
  • 33. The method of claim 2 wherein directing information to be collected includes directing the collection of functional magnetic resonance image data.
  • 34. The method of example 2, further comprising implanting an electrode at least proximate to the stimulation site and applying an electrical stimulation via the electrode.
  • 35. The method of claim 2, further comprising applying electrical stimulation to the patient's brain while directing the information to be collected.
  • 36. The method of claim 2 wherein directing the patient to perform a task includes directing the patient to retrieve a word based on a letter cue, and wherein the method further comprisesapplying electrical stimulation to the patient's brain while directing the information to be collected.
  • 37. The method of claim 2, further comprising locating the stimulation site relative to a fiducial having a fixed location relative to the patient's skull.
  • 38. A method for treating a language disorder, comprising: administering a neuroexcitatory drug to a patient;directing the patient to perform a language-based task, including directing the patient to retrieve a word based on a letter cue;directing information to be collected while the patient performs the language-based task with the neuroexcitatory drug active in the patient's body, the information corresponding to a level of neural activity in the patient's brain while the patient performs the language-based task; andat least reducing a language disorder of the patient by applying an electrical stimulation at least proximate to one or more stimulation sites, with locations of all the stimulation sites for receiving electrical stimulation at the patient's brain being based at least in part on the information, and being proximate the dura mater and outside a cortical surface of the patient's brain.
  • 39. The method of claim 38 wherein directing the patient to perform a language-based task includes directing the patient to perform a task that requires no verbal output.
  • 40. The method of claim 38 wherein directing the patient to perform a language-based task includes directing the patient to silently generate a verb associated with a common noun.
  • 41. The method of claim 38 wherein directing the patient to perform a language-based task includes directing the patient to repeat a noun.
  • 42. The method of claim 38 wherein directing the patient to perform a language-based task includes directing the patient to retrieve a word based on a visual cue.
  • 43. The method of claim 38 wherein directing the patient to perform a language-based task includes directing the patient to respond nonverbally to an oral task that requires the patient to understand the difference between two auditory commands.
  • 44. The method of claim 38, further comprising: administering a neuroexcitatory agent to the patient; andapplying the electrical stimulation while the neuroexcitatory agent is active in the patient's body.
  • 45. The method of claim 38 wherein directing information to be collected includes directing a computer-based routine to collect the information.
  • 46. The method of claim 38, further comprising directing the formation of an image of at least a portion of the patient's brain, with at least a portion of the image having features representative of the information.
  • 47. The method of claim 38 wherein directing information to be collected includes directing the formation an image of at least a portion of the patient's brain, the image including a first region with a characteristic of the first region having a first value, the image further including a second region with a characteristic of the second region having a second value different than the first value.
  • 48. The method of claim 38, further comprising implanting at least one electrode at least proximate to the stimulation site, and wherein applying an electrical stimulation includes applying an electrical signal to the at least one electrode.
  • 49. The method of claim 38 wherein directing a patient to perform a language-based task includes directing the patient to perform a first language-based task and wherein directing information to be collected includes directing first information to be collected while the patient performs the first language-based task, and wherein the method further comprises: directing the patient to perform a second language-based task;directing second information to be collected while the patient performs the second language-based task; anddetermining a location for the stimulation site based on both the first information and the second information.
  • 50. A method for treating a language disorder, comprising: administering a neuroexcitatory drug to a patient;directing the patient to perform a language-based task;directing information to be collected while the patient performs the language-based task with the neuroexcitatory drug active in the patient's body, the information corresponding to a level of neural activity in the patient's brain while the patient performs the language-based task; andat least reducing a language disorder of the patient by applying an electrical stimulation at least proximate to a stimulation site, the location of the stimulation site being based at least in part on the information.
  • 51. The method of claim 50 wherein: directing a patient to perform a language-based task includes directing the patient to respond nonverbally to an oral task that requires the patient to understand the difference between two auditory commands.
  • 52. The method of claim 50 wherein directing the patient to perform a task includes directing the patient to perform a language-based task that requires no verbal output.
  • 53. The method of claim 50 wherein directing the patient to perform a task includes directing the patient to silently generate a verb associated with a common noun.
  • 54. The method of claim 50 wherein directing the patient to perform a task includes directing the patient to repeat a noun.
  • 55. The method of claim 50 wherein directing the patient to perform a task includes directing the patient to retrieve a word based on a letter cue.
  • 56. The method of claim 50 wherein directing the patient to perform a task includes directing the patient to retrieve a word based on a visual cue.
  • 57. The method of claim 50, further comprising not engaging the patient in a speech therapy task while applying the electrical stimulation.
CROSS-REFERENCE TO RELATED APPLICATIONS

The present application relates to and claims priority to pending U.S. Provisional Application No. 60/432,073, entitled “System and Method for Treating Parkinson's Disease and Other Movement Disorders,” filed Dec. 9, 2002, and pending U.S. Provisional Application No. 60/515,309, entitled “Methods for Treating and/or Collecting Information Regarding Neurological Disorders, Including Language Disorders,” filed Oct. 28, 2003, both incorporated herein by reference. The present application also relates to pending U.S. application Ser. No. 10/072,700, filed Feb. 7, 2002, and incorporated herein by reference.

US Referenced Citations (332)
Number Name Date Kind
2716226 Jonas Aug 1955 A
2721316 Shaw Oct 1955 A
3628193 Collins Dec 1971 A
3650276 Burghele et al. Mar 1972 A
3850161 Liss Nov 1974 A
3918461 Cooper Nov 1975 A
4019518 Maurer et al. Apr 1977 A
4030509 Heilman et al. Jun 1977 A
4125116 Fischell Nov 1978 A
4140133 Kastrubin et al. Feb 1979 A
4214804 Little Jul 1980 A
4245645 Picard et al. Jan 1981 A
4308868 Jhabvala Jan 1982 A
4328813 Ray May 1982 A
4340038 McKean Jul 1982 A
4390023 Rise Jun 1983 A
4431000 Butler et al. Feb 1984 A
4474186 Ledley et al. Oct 1984 A
4541432 Molina-Negro et al. Sep 1985 A
4542752 DeHaan et al. Sep 1985 A
4590946 Loeb May 1986 A
4607639 Tanagho et al. Aug 1986 A
4646744 Capel Mar 1987 A
4702254 Zabara Oct 1987 A
4817634 Holleman et al. Apr 1989 A
4844075 Liss et al. Jul 1989 A
4865048 Eckerson Sep 1989 A
4869255 Putz Sep 1989 A
4903702 Putz Feb 1990 A
4969468 Byers et al. Nov 1990 A
5002053 Garcia-Rill et al. Mar 1991 A
5024226 Tan Jun 1991 A
5031618 Mullett Jul 1991 A
5044368 Putz Sep 1991 A
5054906 Lyons Oct 1991 A
5063932 Dahl et al. Nov 1991 A
5092835 Schurig et al. Mar 1992 A
5119832 Xavier Jun 1992 A
5121754 Mullett Jun 1992 A
5143089 Alt Sep 1992 A
5169384 Bosniak et al. Dec 1992 A
5184620 Cudahy et al. Feb 1993 A
5193540 Schulman et al. Mar 1993 A
5215086 Terry, Jr. et al. Jun 1993 A
5215088 Normann et al. Jun 1993 A
5224491 Mehra Jul 1993 A
5255678 Deslauriers et al. Oct 1993 A
5263967 Lyons Nov 1993 A
5269303 Wernicke et al. Dec 1993 A
5271417 Swanson et al. Dec 1993 A
5282468 Klepinski Feb 1994 A
5299569 Wernicke et al. Apr 1994 A
5303705 Nenov Apr 1994 A
5304206 Baker, Jr. et al. Apr 1994 A
5314458 Najafi et al. May 1994 A
5358513 Powell, III et al. Oct 1994 A
5358514 Schulman et al. Oct 1994 A
5370672 Fowler et al. Dec 1994 A
5405375 Ayers et al. Apr 1995 A
5406957 Tansey Apr 1995 A
5411540 Edell et al. May 1995 A
5417719 Hull et al. May 1995 A
5423864 Ljungstroem Jun 1995 A
5423877 Mackey Jun 1995 A
5441528 Chang et al. Aug 1995 A
5458631 Xavier Oct 1995 A
5464446 Dreessen et al. Nov 1995 A
5520190 Benedict et al. May 1996 A
5522864 Wallace et al. Jun 1996 A
5537512 Hsia et al. Jul 1996 A
5540734 Zabara Jul 1996 A
5540736 Haimovish et al. Jul 1996 A
5549655 Erickson Aug 1996 A
5562708 Combs et al. Oct 1996 A
5575813 Edell Nov 1996 A
5591216 Testerman et al. Jan 1997 A
5593432 Crowther et al. Jan 1997 A
5601611 Fayram et al. Feb 1997 A
5611350 John Mar 1997 A
5618531 Cherksey Apr 1997 A
5628317 Starkebaum et al. May 1997 A
5674251 Combs et al. Oct 1997 A
5674264 Carter et al. Oct 1997 A
5676655 Howard, III et al. Oct 1997 A
5683422 Rise Nov 1997 A
5702429 King Dec 1997 A
5707334 Young Jan 1998 A
5711316 Elsberry et al. Jan 1998 A
5713922 King Feb 1998 A
5713923 Ward et al. Feb 1998 A
5716377 Rise et al. Feb 1998 A
5722401 Pietroski et al. Mar 1998 A
5735814 Elsberry et al. Apr 1998 A
5750376 Weiss et al. May 1998 A
5752979 Benabid May 1998 A
5753505 Luskin May 1998 A
5769778 Abrams et al. Jun 1998 A
5772591 Cram Jun 1998 A
5782798 Rise Jul 1998 A
5782873 Collins Jul 1998 A
5792186 Rise Aug 1998 A
5797970 Pouvreau Aug 1998 A
5814014 Elsberry et al. Sep 1998 A
5814092 King Sep 1998 A
5824021 Rise Oct 1998 A
5824030 Yang et al. Oct 1998 A
5832932 Elsberry et al. Nov 1998 A
5833603 Kovacs et al. Nov 1998 A
5833709 Rise et al. Nov 1998 A
5843148 Gijsbers Dec 1998 A
5843150 Dreessen et al. Dec 1998 A
5846196 Siekmeyer et al. Dec 1998 A
5865842 Knuth et al. Feb 1999 A
5871517 Abrams et al. Feb 1999 A
5885976 Sandyk Mar 1999 A
5886769 Zolten Mar 1999 A
5893883 Torgerson et al. Apr 1999 A
5904916 Hirsch May 1999 A
5913882 King Jun 1999 A
5916171 Mayevsky Jun 1999 A
5925070 King et al. Jul 1999 A
5928144 Real Jul 1999 A
5938688 Schiff Aug 1999 A
5938689 Fischell et al. Aug 1999 A
5941906 Barreras et al. Aug 1999 A
5964794 Bolz et al. Oct 1999 A
5975085 Rise Nov 1999 A
5978702 Ward et al. Nov 1999 A
5983140 Smith et al. Nov 1999 A
6006124 Fischell et al. Dec 1999 A
6011996 Gielen et al. Jan 2000 A
6016449 Fischell et al. Jan 2000 A
6018682 Rise Jan 2000 A
6021352 Christopherson et al. Feb 2000 A
6024702 Iversen Feb 2000 A
6026326 Bardy Feb 2000 A
6035236 Jarding et al. Mar 2000 A
6038480 Hrdlicka et al. Mar 2000 A
6040180 Johe Mar 2000 A
6042579 Elsberry et al. Mar 2000 A
6051017 Loeb et al. Apr 2000 A
6052624 Mann Apr 2000 A
6055456 Gerber Apr 2000 A
6057846 Sever, Jr. May 2000 A
6057847 Jenkins May 2000 A
6058331 King May 2000 A
6060048 Cherksey May 2000 A
6061593 Fischell et al. May 2000 A
6066163 John May 2000 A
6094598 Elsberry et al. Jul 2000 A
6095148 Shastri et al. Aug 2000 A
6104956 Naritoku et al. Aug 2000 A
6104960 Duysens et al. Aug 2000 A
6122548 Starkebaum et al. Sep 2000 A
6126657 Edwards et al. Oct 2000 A
6128527 Howard, III et al. Oct 2000 A
6128537 Rise Oct 2000 A
6128538 Fischell et al. Oct 2000 A
6129685 Howard, III Oct 2000 A
6134474 Fischell et al. Oct 2000 A
6149612 Schnapp Nov 2000 A
6152143 Edwards Nov 2000 A
6161044 Silverstone Dec 2000 A
6161045 Fischell et al. Dec 2000 A
6161047 King et al. Dec 2000 A
6176242 Rise Jan 2001 B1
6190893 Shastri et al. Feb 2001 B1
6198958 Ives et al. Mar 2001 B1
6205360 Carter et al. Mar 2001 B1
6205361 Kuzma et al. Mar 2001 B1
6210417 Baudino et al. Apr 2001 B1
6221908 Kilgard et al. Apr 2001 B1
6227203 Rise et al. May 2001 B1
6230049 Fischell et al. May 2001 B1
6236892 Feler May 2001 B1
6246912 Sluijter et al. Jun 2001 B1
6251115 Williams et al. Jun 2001 B1
6263225 Howard, III Jul 2001 B1
6263237 Rise Jul 2001 B1
6280462 Hauser et al. Aug 2001 B1
6301493 Marro et al. Oct 2001 B1
6304787 Kuzma et al. Oct 2001 B1
6319241 King et al. Nov 2001 B1
6339725 Naritoku et al. Jan 2002 B1
6353754 Fischell et al. Mar 2002 B1
6354299 Fischell et al. Mar 2002 B1
6356786 Rezai et al. Mar 2002 B1
6356792 Errico et al. Mar 2002 B1
6360122 Fischell et al. Mar 2002 B1
6366813 DiLorenzo Apr 2002 B1
6375666 Mische Apr 2002 B1
6405079 Ansarinia Jun 2002 B1
6418344 Rezai Jul 2002 B1
6425852 Epstein et al. Jul 2002 B1
6427086 Fischell et al. Jul 2002 B1
6456886 Howard, III et al. Sep 2002 B1
6459936 Fischell et al. Oct 2002 B2
6463328 John Oct 2002 B1
6464356 Sabel et al. Oct 2002 B1
6466822 Pless Oct 2002 B1
6473568 Kashiyama Oct 2002 B2
6473639 Fischell et al. Oct 2002 B1
6480743 Kirkpatrick et al. Nov 2002 B1
6484059 Gielen Nov 2002 B2
6487450 Chen Nov 2002 B1
6497699 Ludvig et al. Dec 2002 B1
6499488 Hunter et al. Dec 2002 B1
6505075 Weiner Jan 2003 B1
6507755 Gozani et al. Jan 2003 B1
6529774 Greene Mar 2003 B1
6539263 Schiff et al. Mar 2003 B1
6549814 Strutz et al. Apr 2003 B1
6556868 Naritoku et al. Apr 2003 B2
6569654 Shastri et al. May 2003 B2
6591138 Fischell et al. Jul 2003 B1
6597954 Pless et al. Jul 2003 B1
6609030 Rezai et al. Aug 2003 B1
6615065 Barrett et al. Sep 2003 B1
6622048 Mann Sep 2003 B1
6631295 Rubinstein et al. Oct 2003 B2
6633780 Berger Oct 2003 B1
6647296 Fischell et al. Nov 2003 B2
6658299 Dobelle Dec 2003 B1
6665562 Gluckman et al. Dec 2003 B2
6684105 Cohen et al. Jan 2004 B2
6687525 Llinas Feb 2004 B2
6690974 Archer Feb 2004 B2
6708064 Rezai Mar 2004 B2
6725094 Saberski Apr 2004 B2
6731978 Olsen et al. May 2004 B2
6764498 Mische Jul 2004 B2
6782292 Whitehurst Aug 2004 B2
6788975 Whitehurst et al. Sep 2004 B1
6795737 Gielen et al. Sep 2004 B2
6810286 Donovan et al. Oct 2004 B2
6839594 Cohen et al. Jan 2005 B2
6850802 Holsheimer et al. Feb 2005 B2
6873872 Gluckman et al. Mar 2005 B2
6892097 Holsheimer May 2005 B2
6895280 Meadows et al. May 2005 B2
6898464 Edell et al. May 2005 B2
6907296 Doan et al. Jun 2005 B1
6922590 Whitehurst Jul 2005 B1
6934580 Osorio et al. Aug 2005 B1
6944497 Stypulkowski Sep 2005 B2
6944501 Pless Sep 2005 B1
6949081 Chance Sep 2005 B1
6959215 Gliner et al. Oct 2005 B2
6990377 Gliner et al. Jan 2006 B2
7006859 Osorio et al. Feb 2006 B1
7010351 Firlik et al. Mar 2006 B2
7015816 Wildman et al. Mar 2006 B2
7024247 Gliner et al. Apr 2006 B2
7050856 Stypulkowski May 2006 B2
7065412 Swoyer Jun 2006 B2
7107097 Stern et al. Sep 2006 B2
7107104 Keravel et al. Sep 2006 B2
7146222 Boling Dec 2006 B2
7149586 Greenberg et al. Dec 2006 B2
7184840 Stolz et al. Feb 2007 B2
7187968 Wolf et al. Mar 2007 B2
7187977 Paul, Jr. Mar 2007 B2
7191018 Gielen et al. Mar 2007 B2
7346395 Lozano et al. Mar 2008 B2
20020028072 Kashiyama Mar 2002 A1
20020087201 Firlik Jul 2002 A1
20020091419 Firlik et al. Jul 2002 A1
20020099295 Gil et al. Jul 2002 A1
20020099412 Fischell et al. Jul 2002 A1
20020138101 Suda et al. Sep 2002 A1
20020169485 Pless et al. Nov 2002 A1
20030074032 Gliner Apr 2003 A1
20030078633 Firlik et al. Apr 2003 A1
20030088274 Gliner et al. May 2003 A1
20030097161 Firlik et al. May 2003 A1
20030114886 Gluckman et al. Jun 2003 A1
20030125786 Gliner et al. Jul 2003 A1
20030130706 Sheffield et al. Jul 2003 A1
20030149457 Tcheng et al. Aug 2003 A1
20030176901 May Sep 2003 A1
20030187490 Gliner Oct 2003 A1
20040073270 Firlik et al. Apr 2004 A1
20040082847 McDermott Apr 2004 A1
20040088024 Firlik et al. May 2004 A1
20040092809 DeCharms May 2004 A1
20040102828 Lowry et al. May 2004 A1
20040111127 Gliner et al. Jun 2004 A1
20040131998 Marom et al. Jul 2004 A1
20040138550 Hartlep et al. Jul 2004 A1
20040158298 Gliner Aug 2004 A1
20040176831 Gliner et al. Sep 2004 A1
20040181263 Balzer et al. Sep 2004 A1
20040236388 Gielen et al. Nov 2004 A1
20040249422 Gliner et al. Dec 2004 A1
20050004620 Singhal et al. Jan 2005 A1
20050015129 Mische Jan 2005 A1
20050021104 DiLorenzo Jan 2005 A1
20050021105 Firlik et al. Jan 2005 A1
20050021106 Firlik et al. Jan 2005 A1
20050021107 Firlik et al. Jan 2005 A1
20050021118 Genau et al. Jan 2005 A1
20050070971 Fowler et al. Mar 2005 A1
20050075679 Gliner et al. Apr 2005 A1
20050075680 Lowry et al. Apr 2005 A1
20050096701 Donovan et al. May 2005 A1
20050113882 Cameron et al. May 2005 A1
20050119712 Shafer Jun 2005 A1
20050154425 Boveja et al. Jul 2005 A1
20050154426 Boveja et al. Jul 2005 A1
20050182453 Whitehurst Aug 2005 A1
20050228451 Jaax et al. Oct 2005 A1
20060004422 De Ridder Jan 2006 A1
20060004423 Boveja et al. Jan 2006 A1
20060015153 Gliner et al. Jan 2006 A1
20060095088 De Ridder May 2006 A1
20060106430 Fowler et al. May 2006 A1
20060106431 Wyler et al. May 2006 A1
20060129205 Boveja et al. Jun 2006 A1
20060173522 Osorio Aug 2006 A1
20060217782 Boveja et al. Sep 2006 A1
20060241717 Whitehurst et al. Oct 2006 A1
20070032834 Gliner et al. Feb 2007 A1
20070055320 Weinand Mar 2007 A1
20070060974 Lozano Mar 2007 A1
20070088403 Wyler et al. Apr 2007 A1
20070088404 Wyler et al. Apr 2007 A1
20070100398 Sloan May 2007 A1
20070100598 Zeidman May 2007 A1
20070179534 Firlik et al. Aug 2007 A1
20070179558 Gliner et al. Aug 2007 A1
20080045775 Lozano Feb 2008 A1
20080139870 Gliner et al. Jun 2008 A1
Foreign Referenced Citations (19)
Number Date Country
19750043 May 1999 DE
0214527 Mar 1987 EP
0319844 Jun 1989 EP
0 998 958 Oct 2000 EP
1145736 Oct 2001 EP
1180056 Nov 2003 EP
WO 8707511 Dec 1987 WO
WO 9407564 Apr 1994 WO
WO 9521591 Aug 1995 WO
WO-9745160 Dec 1997 WO
WO 9806342 Feb 1998 WO
WO 0197906 Dec 2001 WO
WO 0209811 Feb 2002 WO
WO 0236003 May 2002 WO
WO 0238031 May 2002 WO
WO 0238217 May 2002 WO
WO 03082402 Mar 2003 WO
WO 03043690 May 2003 WO
WO-03101532 Dec 2003 WO
Related Publications (1)
Number Date Country
20050033378 A1 Feb 2005 US
Provisional Applications (2)
Number Date Country
60432073 Dec 2002 US
60515309 Oct 2003 US